Medprin Regenerative Medical Technologies Co., Ltd.

SZSE:301033 Stock Report

Market Cap: CN¥2.8b

Medprin Regenerative Medical Technologies Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Jianhua Wang

Chief executive officer

CN¥1.3m

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownership0.01%
Management average tenureno data
Board average tenure1.6yrs

Recent management updates

Recent updates

Medprin Regenerative Medical Technologies Co., Ltd. (SZSE:301033) Looks Just Right With A 38% Price Jump

May 08
Medprin Regenerative Medical Technologies Co., Ltd. (SZSE:301033) Looks Just Right With A 38% Price Jump

CEO

Jianhua Wang (56 yo)

less than a year

Tenure

CN¥1,318,900

Compensation

Mr. Jianhua Wang is Director of Medprin Regenerative Medical Technologies Co. Ltd. from May 18, 2023 and serves as General Manager since April 17, 2024 and was its Deputy General Manager until April 17, 20...


Board Members

NamePositionTenureCompensationOwnership
Jianhua Wang
GM & Director1.6yrsCN¥1.32m0.011%
CN¥ 324.0k
Yahong Luo
CFO, Deputy GM & Non-Independent Directorno dataCN¥759.40k0.059%
CN¥ 1.7m
Xiaoyan Long
Board Secretary & Non-Independent Director2.7yrsCN¥574.80k0.012%
CN¥ 336.7k
Xiaoming Chen
Independent Directorless than a yearno datano data
Jianhua Chen
Independent Directorless than a yearno datano data
Meifu Yuan
Non-Independent Directorno datano data4.39%
CN¥ 123.8m
Yuyu Yuan
Chairman of the Boardno dataCN¥772.50k16.61%
CN¥ 468.3m
Haiying Zheng
Directorno datano datano data
Meiling Mo
Supervisorno datano datano data
Xian Zhuang
Chairman of the Supervisory Board1.7yrsno datano data
Qing Yuan
Independent Directorless than a yearno datano data
Jinmei Liang
Supervisor1.6yrsno datano data

1.6yrs

Average Tenure

44yo

Average Age

Experienced Board: 301033's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 00:48
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Medprin Regenerative Medical Technologies Co., Ltd. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Song YangTianfeng Securities Brokerage Co., Ltd